 Theravance Biopharma Inc. TBPH, 0.20 said Monday its board has authorized a 250 million capital return program, that includes buying back its own stock from GSK Plc GSK, -0.61 . The company will purchase GSKs entire holdings of about 9.6 million shares at 9.75 a share with the closing expected Tuesday. 